- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00790894
Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT) (HIT)
May 17, 2011 updated by: Hellenic Cooperative Oncology Group
Phase II Randomized Trial of Ixabepilone Administered Weekly or Every Three Weeks in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Chemotherapy in the Neo-adjuvant or Adjuvant Setting
This is a Phase II Randomized, Open Label, Non-comparative Trial (Parallel Assignment and Efficacy Study) for patients with HER-2 Negative Metastatic Breast Cancer Previously Treated With chemotherapy in the Neo-Adjuvant or Adjuvant Setting.Patients will be randomized to receive Ixabepilone either every three weeks, or weekly for three weeks followed by one week off.
Patients will be treated until consent withdrawal, intolerable toxicity or documented disease progression
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Patients with measurable metastatic breast cancer that have been treated in the adjuvant or neo-adjuvant setting with chemotherapy will be considered for this study.
Subjects must not have received cytotoxic chemotherapy for locally recurrent/metastatic disease.
Patients who fulfil the eligibility criteria, and have signed inform consent for the trial will be centrally randomized by electronic means to one of two ixabepilone treatment arms.
Stratification factors will include: time to recurrence from adjuvant treatment, calculated from the date of the last dose of adjuvant treatment to the date of relapse (≤ 1 year vs. > 1 year); and previous chemotherapy with taxane regimen in the neo-adjuvant or adjuvant setting (yes vs. no).
Randomization will be balanced by site.Treatment Protocol· Arm A [standard once every three weeks schedule]:Ixabepilone [BMS-247550] will be administered on Day 1 (D1) every three weeks as a 3-hour infusion at a dose of 40 mg/m2.
· Arm B [weekly schedule]:Ixabepilone [BMS-247550] will be administered weekly for three weeks as a 3-hour infusion at a dose of 20 mg/m2, followed by one week-off.Treatment can be continued until consent withdrawal by the patient, intolerable toxicity or documented disease progression.
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Athens, Greece, 11527
- Hippokration General Hospital, Oncology Department
-
Athens, Greece, 12462
- University Hospital Attikon, Second Department of Internal Medicine, Oncology Section
-
Athens, Greece, 13122
- Agii Anargiri Cancer Hospital, Third Department of Medical Oncology
-
Athens, Greece, 15123
- Hygeia Hospital, First Deparment of Medical Oncology
-
Athens, Greece, 15123
- Hygeia Hospital, Second Department of Medical Oncology
-
Athens, Greece
- Alexandra Hospital, Department of Clinical Therapeutics
-
Ioannina, Greece, 45500
- University General Hospital of Ioannina, Medical Oncology Department
-
Larisa, Greece, 41110
- University Hospital of Larisa, Department of Medical Oncology
-
Patras, Greece, 265 00
- University Hospital of Patras, Department of Medicine, Division of Oncology
-
Piraeus, Greece, 18547
- Metropolitan Hospital, Second Dept of Medical Oncology
-
Piraeus, Greece, 18547
- Metropolitan Hospital, First Department of Medical Oncology
-
Thessaloniki, Greece, 54007
- "Theageneio" Cancer Hospital, Third Department of Medical Oncology
-
Thessaloniki, Greece, 56429
- "Papageorgiou" General Hospital, Department of Medical Oncology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Written informed consent
- Female patients aged 18 to 75 years inclusive
- Prior chemotherapy in the adjuvant or neo-adjuvant setting
- Diagnosis of HER-2 negative (HER-2 <2+ by immunohistochemistry and/or FISH negative) metastatic breast adenocarcinoma confirmed by the pathology department of the enrolling institution
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Life expectancy of at least 12 weeks
- Measurable disease by the Response Criteria in Solid Tumors (RECIST) method
- Laboratory values within the specified ranges within 1 week of study enrolment:
- Absolute neutrophil count of ≥ 1.5 x 109/L
- Thrombocyte count of ≥ 100 x 109/L
- Subjects must not have received cytotoxic chemotherapy for locally recurrent/metastatic disease
- Prior hormonal therapy for locally recurrent or metastatic disease allowed
- AST and ALT ≤ 2.5 x ULN
- Bilirubin ≤ 1.5 x ULN
- Recovery from prior palliative radiotherapy for bone metastases
Exclusion Criteria:
- Because of concerns that ixabepilone metabolism may be inhibited by potent cytochrome P450 3A4 inhibitors, patients must not receive the following medications, up to 72 hours prior to initiation of study therapy and until they come off treatment with ixabepilone: amprenavir, delavirdine, voriconazole, erythromycin, cyclosporine, troleandomycin, terfenadine, ketoconazole, nelfinavir, and ritonavir
- Patients with CTC grade 2 or greater neuropathy at baseline
- Patients with any history or evidence of brain an/or leptomenigneal metastasis
- Patients with clinically significant cardiac disease (e.g. unstable angina, congestive heart failure, myocardial infarction) within 6 months from study entry
- Psychiatric disorders or other conditions rendering the subject incapable of complying with the requirements of the protocol
- Any concurrent active malignancy other than non-melanoma skin cancer or in situ carcinoma of the cervix (subjects with a history of previous malignancies but without evidence of disease for 5 years will be allowed to enter the trial)
- Prior severe HSR to agents containing Cremophor EL
- Women of childbearing potential (WOCBP) who are unwilling or unable to use an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks from the last dose of ixabepilone, in such a manner that the risk of pregnancy is minimized WOCBP include: any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea ≥ 12 consecutive months; women on hormone replacement therapy with documented FSH level > 35mIU/mL. Even women who are practising abstinence or whom their partner is sterile (e.g. vasectomy) should be considered of childbearing potential.
- Women who are pregnant or breastfeeding
- Women with a positive pregnancy test on enrolment or prior to study therapy
- No other concomitant chemotherapy, endocrine therapy, immunotherapy, radiation therapy (except for palliative radiotherapy for bone metastases) or investigational treatments are allowed during subject's participation in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 1
|
Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.
Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
|
EXPERIMENTAL: 2
|
Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.
Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary endpoint of the study is the best Overall Response (OR).
Time Frame: At 6, 12 and 24 weeks
|
At 6, 12 and 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy endpoints: time to response, PFS, TTF, duration of response
Time Frame: Duration of the study
|
Duration of the study
|
OS Toxicity endpoints: incidence of hematological and non-hematological toxicities
Time Frame: Duration of the study
|
Duration of the study
|
Translational endpoints
Time Frame: Duration of the study
|
Duration of the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: George Fountzilas, Papageorgiou General Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2008
Primary Completion (ACTUAL)
April 1, 2011
Study Completion (ACTUAL)
May 1, 2011
Study Registration Dates
First Submitted
November 13, 2008
First Submitted That Met QC Criteria
November 13, 2008
First Posted (ESTIMATE)
November 14, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
May 18, 2011
Last Update Submitted That Met QC Criteria
May 17, 2011
Last Verified
May 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HE 11A08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi SankyoRecruitingAdvanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast CarcinomaFrance
Clinical Trials on ixabepilone
-
Weill Medical College of Cornell UniversityBristol-Myers SquibbCompletedMetastatic Breast CancerUnited States
-
R-PharmNational Cancer Institute (NCI); Memorial Sloan Kettering Cancer CenterCompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)CompletedLymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Cedars-Sinai Medical CenterBristol-Myers SquibbTerminatedUrogenital Neoplasms | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Male | Prostatic Neoplasms | Prostatic Diseases | Genital Diseases, MaleUnited States
-
Eisai Inc.Completed
-
R-PharmCompletedSolid MalignanciesUnited States
-
R-PharmCompleted
-
R-PharmCompletedStomach NeoplasmsKorea, Republic of, Taiwan, Japan, Singapore, Hong Kong